posteditor

posteditor

Curis Provides First Quarter 2026 Business Update

B Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., May 12, 2026 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3…